Press monitoring
Eating transgenic tobacco prevents cervical cancer
7.4.2006 | Press monitoring
Human Papillomaviruses (HPV) are the causative agents for cervical, skin, head and neck tumors. In developing countries, cervical cancer is one of the main causes of cancer-related deaths. However, Italian researchers have now developed an immunologically active, cost-efficient vaccine against HPV.
Drugs from llamas? Belgian firm eyes IPO next year
7.4.2006 | Press monitoring
A Belgian biotechnology company using llama DNA to develop a new class of drugs hopes to float on the Euronext stock market next year, its incoming chief executive said on Monday.
US, African scientists seek biotech answer to hunger
7.4.2006 | Press monitoring
As he pores over plant tissue and petri dishes in a biotech seed lab in Johnston, Iowa, Luke Mehlo is half a world away from his home in South Africa.
US scientists make pigs with heart-healthy fats
7.4.2006 | Press monitoring
U.S. scientists said on Sunday they had genetically engineered pigs that make beneficial fatty acids and may one day serve as a healthier source of pork chops or bacon.
OHSU Study Aims To Halt Alzheimer's By Blocking Enzyme
7.4.2006 | Press monitoring
Inhibiting gamma secretase may prevent amyloid plaque build-up thought to trigger disease, but trials continue
Small science
7.4.2006 | Press monitoring
Technology: The nanotech future is just beginning | Lynde Langdon
Glaxo starts human tests of bird flu vaccines
6.4.2006 | Press monitoring
WASHINGTON -- GlaxoSmithKline said yesterday it has started human trials of two new bird flu vaccines and that if the treatments work, they could be ready to manufacture by the end of the year.
Powerful new tool for studying brain development
6.4.2006 | Press monitoring
The mouse Brain Gene Expression Map at St. Jude shows where and when genes influence development of the brain and helps researchers study links between gene mutations and cancers
Allergy's ragweed vaccine passes key trial
6.4.2006 | Press monitoring
Allergy Therapeutics received a boost today after the hay fever treatment outfit passed a key phase III clinical efficacy and safety trial for its ragweed allergy vaccine.
No winners in drug fight
6.4.2006 | Press monitoring
The protesters have had the chief executive in their sights for some time now. They've paraded outside his corporate offices. They've lobbied the companies he serves as a board member. They've flooded his phones with calls.
